Back

Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials

3 September 2019 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 6 - Lipid management and outcome Lipid-Lowering Agents ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Paul Guedeney

Pitie Salpetriere APHP University Hospital, Paris (France)

6 More presentations in this session

Presentation thumbnail
Professor A. Her (Chuncheon, KR)
Abstract
Presentation thumbnail
Assistant Professor J. Dopheide (Thun, CH)
Abstract Slides
Presentation thumbnail
Doctor C. Ballantyne (Houston, US)
Abstract Slides
Presentation thumbnail
Doctor E. Fountas (Athens, GR)
Abstract Slides
Presentation thumbnail
Doctor T. Konishi (Sapporo, JP)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 6 - Lipid management and outcome

The Event

Event poster

ESC Congress 2019

3 September 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Comparative effectiveness of novel anti-hyperlipidemic drugs in adults with hyperlipidemia: a systematic review and bayesian network meta-analysis
4 April 2025
thumbnail
Congress Presentation
Meta-analysis assessing cardiovascular outcomes with febuxostat versus allopurinol for patients with gout
27 August 2021
thumbnail
Congress Presentation
Gender-related differences in efficacy, safety and adherence of PCSK9 inhibitors in real-world clinical practice: insights from the AT-TARGET-IT Registry
30 August 2026
thumbnail
Congress Presentation
Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources